# Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

> **NCT00509288** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Melanoma
- Skin Cancer

## Interventions

- **BIOLOGICAL:** autologous anti-MART-1 F5 T-cell receptor
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes

## Key facts

- **NCT ID:** NCT00509288
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2011-07
- **Final completion:** 2012-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509288, "Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00509288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*